CDKN2A and neoplasm: Notably, only tumor cell explants with a BRAFV600E-mutated background harboring loss of CDKN2A expression in combination with TERT promoter mutation developed into stable, immortalized cell lines (Table 1, Additional file 3: Figure S3).